236 related articles for article (PubMed ID: 26871836)
1. GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Wang JJ; Dong M; He XH; Li YX; Wang WH; Liu P; Yang JL; Gui L; Zhang CG; Yang S; Zhou SY; Shi YK
Medicine (Baltimore); 2016 Feb; 95(6):e2787. PubMed ID: 26871836
[TBL] [Abstract][Full Text] [Related]
2. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D
Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIE extranodal natural killer/T-cell lymphoma, nasal type.
Tian S; Li R; Wang T; Wang S; Tao R; Hu X; Ding H
Cancer Med; 2019 Jul; 8(7):3349-3358. PubMed ID: 31050212
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
Qi F; Dong M; He X; Li Y; Wang W; Liu P; Yang J; Gui L; Zhang C; Yang S; Zhou S; Shi Y
Ann Hematol; 2017 Feb; 96(2):245-251. PubMed ID: 27858107
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience.
Batgi H; Başcı S; Dal MS; Kızıl Çakar M; Uncu Ulu B; Yiğenoğlu TN; Özcan N; Kılınç A; Merdin A; Yıldız J; Bakırtaş M; Şahin D; Darçın T; İskender D; Baysal NA; Altuntaş F
Turk J Med Sci; 2021 Apr; 51(2):685-692. PubMed ID: 33237657
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
8. Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma.
Zhong DT; Shi CM; Chen Q; Huang JZ; Liang JG
Ann Hematol; 2012 Nov; 91(11):1757-63. PubMed ID: 22790106
[TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
Huang Y; Yang J; Liu P; Zhou S; Gui L; He X; Qin Y; Zhang C; Yang S; Xing P; Sun Y; Shi Y
Ann Hematol; 2017 Sep; 96(9):1477-1483. PubMed ID: 28695246
[TBL] [Abstract][Full Text] [Related]
10. Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell lymphoma.
Ke QH; Zhou SQ; Du W; Liang G; Lei Y; Luo F
Blood Cancer J; 2014 Dec; 4(12):e267. PubMed ID: 25501024
[TBL] [Abstract][Full Text] [Related]
11. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Zhang L; Li S; Jia S; Nan F; Li Z; Cao J; Fan S; Zhang C; Su L; Wang J; Xue H; Zhang M
Oncotarget; 2016 Sep; 7(36):58396-58404. PubMed ID: 27517317
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.
Zhang L; Jia S; Ma Y; Li L; Li X; Wang X; Fu X; Ma W; Qin Y; Li W; Wu J; Sun Z; Zhang X; Nan F; Chang Y; Li Z; Zhang D; Wang G; Yan J; Su L; Wang J; Xue H; Young KH; Zhang M
Oncotarget; 2016 Aug; 7(34):55721-55731. PubMed ID: 27384676
[TBL] [Abstract][Full Text] [Related]
13. A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type.
Lin N; Song Y; Zheng W; Tu M; Xie Y; Wang X; Ping L; Ying Z; Zhang C; Deng L; Liu W; Zhu J
J Hematol Oncol; 2013 Jul; 6():44. PubMed ID: 23816178
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study.
Qi F; Wang WH; He XH; Chen B; Gui L; Fang H; Liu P; Wang SL; Yang JL; Song YW; Yang S; Qi SN; Zhou SY; Li YX; Dong M
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):61-70. PubMed ID: 30102205
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
Crump M; Baetz T; Couban S; Belch A; Marcellus D; Howson-Jan K; Imrie K; Myers R; Adams G; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R
Cancer; 2004 Oct; 101(8):1835-42. PubMed ID: 15386331
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.
Zhou Z; Li X; Chen C; Li X; Zhang L; Li L; Wang X; Ma W; Fu X; Wu J; Sun Z; Zhang X; Li Z; Yan J; Chang Y; Lu L; Qin B; Li X; Wen J; Zhang M
Ann Hematol; 2014 Nov; 93(11):1889-94. PubMed ID: 24923454
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
Wang JH; Wang L; Liu CC; Xia ZJ; Huang HQ; Lin TY; Jiang WQ; Lu Y
Oncotarget; 2016 May; 7(20):29092-101. PubMed ID: 27093153
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of patients treated with SVILE
Wei L; Yang L; Ye J; Cong J; Li X; Yao N; Yang J; Cui X; Ding J; Wu Y; Wang J
Cancer Biol Med; 2020 Aug; 17(3):795-804. PubMed ID: 32944407
[No Abstract] [Full Text] [Related]
20. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
